Association of hyperdense middle cerebral artery sign with clinical outcome in patients treated with tissue plasminogen activator.

BACKGROUND AND PURPOSE The hyperdense middle cerebral artery sign (HMCAS) is a marker of thrombus in the middle cerebral artery. The aim of our study was to find out the frequency of the HMCAS, its association with initial neurological severity and early parenchymal ischemic changes on CT, its relevance to clinical outcome, and the efficacy of intravenous recombinant tissue plasminogen activator (rtPA) in patients with the HMCAS. METHODS Secondary analysis of the data from 620 patients who received either rtPA or placebo in the European Cooperative Acute Stroke Study I (ECASS I), a double-blind, randomized, multicenter trial. The baseline CT scans were obtained within 6 hours from the onset of symptoms. Functional and neurological outcomes were assessed using the modified Rankin Scale and the Scandinavian Stroke Scale at day 90. RESULTS We found an HMCAS in 107 patients(17.7%). The initial neurological deficit was more severe in patients with the HMCAS than in those lacking this sign (P<0.0001). Early cerebral edema and mass effect were also more common in patients with the HMCAS (P<0.0001). The HMCAS was related to the risk of poor functional outcome (grade of 3 to 6 on the modified Rankin Scale) on univariate analysis: 90 patients (84%) with the HMCAS and 310 patients (62%) lacking this sign were dependent or dead at day 90 (P<0.0001). However, this association was no longer significant in a logistic model accounting for the effect of age, sex, treatment with rtPA, initial severity of neurological deficit and early parenchymal ischemic changes on CT. Patients with the HMCAS who were given rtPA had better neurological recovery than those who received placebo (P=0.0297). CONCLUSIONS The HMCAS is associated with severe brain ischemia and poor functional outcome. However, it has no significant independent prognostic value when accounting for the effect of initial severity of neurological deficit and of early parenchymal ischemic changes on CT. Patients with the HMCAS may benefit from intravenous rtPA.

[1]  L. Bozzao,et al.  Hyperdense middle cerebral artery CT sign. Comparison with angiography in the acute phase of ischemic supratentorial infarction. , 1991, Neuroradiology.

[2]  W Hacke,et al.  Sensitivity and prognostic value of early CT in occlusion of the middle cerebral artery trunk. , 1994, AJNR. American journal of neuroradiology.

[3]  L. Antonutti,et al.  Increased density in the middle cerebral artery by nonenhanced computed tomography. Prognostic value in acute cerebral infarction. , 1993, European neurology.

[4]  T Moulin,et al.  Early CT signs in acute middle cerebral artery infarction , 1996, Neurology.

[5]  J. Broderick,et al.  Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy. , 1996, AJNR. American journal of neuroradiology.

[6]  D. Leys,et al.  Prevalence and Significance of Hyperdense Middle Cerebral Artery in Acute Stroke , 1992, Stroke.

[7]  Lippincott Williams Wilkins,et al.  Multicenter Trial of Hemodilution in Ischemic Stroke — Background and Study Protocol , 1985, Stroke.

[8]  J. Thompson,et al.  An early CT sign of ischemic infarction: increased density in a cerebral artery. , 1987, AJR. American journal of roentgenology.

[9]  M. Pessin,et al.  Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. , 1993, AJNR. American journal of neuroradiology.

[10]  L. Ketonen,et al.  Dense middle cerebral artery sign: an indicator of poor outcome in middle cerebral artery area infarction. , 1987, Journal of neurology, neurosurgery, and psychiatry.

[11]  A. Fox,et al.  CT visualization of intracranial arterial thromboembolism. , 1983, Stroke.

[12]  M. Kaste,et al.  The European Cooperative Acute Stroke Study (ECASS) , 1993 .

[13]  M. Kaste,et al.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) , 1995, JAMA.